Marcadores Tumorales

Downloaded from bmj.com on 3 June 2009

Regular review: Tumour markers in malignancies
Annika Lindblom and Annelie Liljegren BMJ 2000;320;424-427 doi:10.1136/bmj.320.7232.424

Updated information and services can be found at: http://bmj.com/cgi/content/full/320/7232/424

These include:

References

This article cites 33 articles, 11 of which can be accessed free at:http://bmj.com/cgi/content/full/320/7232/424#BIBL 5 online articles that cite this article can be accessed at: http://bmj.com/cgi/content/full/320/7232/424#otherarticles

Rapid responses

7 rapid responses have been posted to this article, which you can access for free at: http://bmj.com/cgi/content/full/320/7232/424#responses You can respond to this article at: http://bmj.com/cgi/eletter-submit/320/7232/424Email alerting service

Receive free email alerts when new articles cite this article - sign up in the box at the top left of the article

Topic collections

Articles on similar topics can be found in the following collections Epidemiologic studies (9871 articles) Molecular genetics (1488 articles) Immunology (including allergy) (13937 articles) Cervical cancer (372 articles) Cervicalscreening (265 articles) Breast cancer (2035 articles) Gynecological cancer (672 articles) Urological cancer (665 articles) Screening (oncology) (1795 articles) Urological surgery (2353 articles) Screening (epidemiology) (3294 articles) Internet (1343 articles) Screening (public health) (3304 articles)

Correction

A correction has been published for this article. The correction is available onlineat: http://bmj.com/cgi/content/full/320/7238/867/a

To Request Permissions go to: http://group.bmj.com/group/rights-licensing/permissions To order reprints go to: http://journals.bmj.com/cgi/reprintform To subscribe to BMJ go to: http://resources.bmj.com/bmj/subscribers

Downloaded from bmj.com on 3 June 2009

Notes

To Request Permissions go to:http://group.bmj.com/group/rights-licensing/permissions To order reprints go to: http://journals.bmj.com/cgi/reprintform To subscribe to BMJ go to: http://resources.bmj.com/bmj/subscribers

Clinical review

Downloaded from bmj.com on 3 June 2009

Regular review Tumour markers in malignancies
Annika Lindblom, Annelie Liljegren
In western Europe today, a third of all people develop a malignant disease at least once in theirlifetime. Treatment has improved, and for many diseases, such as leukaemia and testicular cancer, the prognosis is much better today than it was 20 years ago. Screening for early diagnosis has also led to lower mortality for diseases such as breast cancer and cervical cancer; many malignancies, however, are still diagnosed after the metastatic process has already started, indicating a poor prognosis.Tumour markers are usually proteins associated with a malignancy and might be clinically usable in patients with cancer. A tumour marker can be detected in a solid tumour, in circulating tumour cells in peripheral blood, in lymph nodes, in bone marrow, or in other body fluids (ascites, urine, and stool). A tumour marker may be used to define a particular disease entity, in which case it may be usedfor diagnosis, staging, or population screening. Markers may also be used to detect the presence of occult metastatic disease, to monitor response to treatment, or to detect recurrent disease (table). Recently they have even been used as targets for therapeutic intervention in clinical trials.

Department of Clinical Genetics, Karolinska Hospital, S171 76 Stockholm, Sweden Annika Lindblomclinical geneticist Department of South Stockholm Oncology, Huddinge University Hospital, Sweden Annelie Liljegren oncologist Correspondence to: A Lindblom annika.lindblom@ cmm.ki.se
BMJ 2000;320:424–7

Summary points
Tumour markers are commonly proteins associated with malignancy, offering a putative clinical use in cancer A tumour marker can be detected in a solid tumour, in circulating tumour...